Clinical Trial Update: Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects [Phase 1]

View source ↗

Summary

A Phase 1 study in healthy subjects evaluated the potential pharmacokinetic interaction and renal effects when bumetanide (1 mg) is co-administered with dapagli…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• BUMETANIDE (bumetanide)
• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED